{"schema_version":"1.0","type":"article","title":"平台型 Biotech 的授權收入是同業的 5 倍？","url":"https://drugnews.com.tw/articles/2026-04-25-biotech-5.html","markdown_url":"https://drugnews.com.tw/articles/2026-04-25-biotech-5.md","lang":"zh-Hant","date":"2026-04-25","publish_at":"2026-04-25T10:30:00+08:00","updated_at":"2026-04-25","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","BD","臨床數據","生技投資","製藥巨頭"],"summary":"如果把 Biotech 的商業模式拆開來看，最容易被低估、但其實最值錢的一種公司，往往不是手上只有一顆明星分子的資產型公司，而是那些擁有底層技術引擎的平台型公司。","key_points":[],"facts":[],"sections":["為什麼平台型 Biotech 的授權收入，常常是同業的 5 倍？","🔹不是比較會講故事，而是比較容易讓大藥廠相信：你買到的是一台機器","🔹平台賣的不是雞蛋，而是會持續下蛋的雞","🔹argenx：最教科書級的案例","🔹平台真正可怕的，不只是多生幾顆分子，而是 BD 選項更多","🔹平台型公司真正值錢的地方，是重新定義 Biotech 的價值創造方式","🔹結語"],"references":[{"title":"[0]:各公司官網＆公開資料","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"Realized value of platform-based biotech: a retrospective analysis of 220 companies - Recon Strategy","source":"","date":"","url":""},{"title":"We explore four hypothesized value drivers of platform-based companies and evaluate the actual value achieved 10-15 years out from initial capital raise. We found that discovery platforms showed the highest lead asset success rates, significantly more out","source":"","date":"","url":""},{"title":"reconstrategy.com","source":"","date":"","url":""},{"title":"\"Realized value of platform-based biotech: a retrospective analysis of 220 companies - Recon Strategy\"","source":"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"www.us.argenx.com","source":"","date":"","url":""},{"title":"https://www.us.argenx.com/news/2019/argenx-announces-closing-exclusive-global-collaboration-and-license-agreement-cusatuzumab-argx","source":"","date":"","url":"https://www.us.argenx.com/news/2019/argenx-announces-closing-exclusive-global-collaboration-and-license-agreement-cusatuzumab-argx"},{"title":"www.us.argenx.com","source":"","date":"","url":""},{"title":"\"argenx","source":"argenx announces closing of exclusive global collaboration and license agreement for cusatuzumab (ARGX-110) with Janssen \"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"www.us.argenx.com","source":"","date":"","url":""},{"title":"https://www.us.argenx.com/news/2026/press-release-3245199","source":"","date":"","url":"https://www.us.argenx.com/news/2026/press-release-3245199"},{"title":"www.us.argenx.com","source":"","date":"","url":""},{"title":"\"argenx","source":"argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update\"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"Start your Substack","source":"","date":"","url":""},{"title":"Thoughts and updates on platform typology and partnering dynamics","source":"","date":"","url":""},{"title":"centuryofbio.com","source":"","date":"","url":""},{"title":"\"On biotech platform strategy\"","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：平台型 Biotech 的授權收入是同業的 5 倍？（圖 1）","url":"https://drugnews.com.tw/assets/articles/biotech-5/dcard-01.webp"},{"alt":"Dcard 原圖：平台型 Biotech 的授權收入是同業的 5 倍？（圖 2）","url":"https://drugnews.com.tw/assets/articles/biotech-5/dcard-02.webp"},{"alt":"Dcard 原圖：平台型 Biotech 的授權收入是同業的 5 倍？（圖 3）","url":"https://drugnews.com.tw/assets/articles/biotech-5/dcard-03.webp"},{"alt":"Dcard 原圖：平台型 Biotech 的授權收入是同業的 5 倍？（圖 4）","url":"https://drugnews.com.tw/assets/articles/biotech-5/dcard-04.png"},{"alt":"Dcard 原圖：平台型 Biotech 的授權收入是同業的 5 倍？（圖 5）","url":"https://drugnews.com.tw/assets/articles/biotech-5/dcard-05.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/biotech-5/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-04-25）。平台型 Biotech 的授權收入是同業的 5 倍？。https://drugnews.com.tw/articles/2026-04-25-biotech-5.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-04-25-biotech-5-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}